Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Relatlimab in Renal Medullary Carcinoma
NCT05347212Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2022
- Primary completion
- Jul 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, relatlimab in renal medullary carcinoma (RMC), sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2022; status: active, not recruiting.
02
Drugs
nivolumabrelatlimab
03
Conditions
renal medullary carcinoma (RMC)
Beyond the preview
Go deeper on NCT05347212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05347212.